CD3 bispecific for the treatment of ROR2-positive nsclc
Ended Project Grant Awarded Last action
- Award ID
- R43CA285040
- Recipient
-
Traverse Biotech II Inc. UEI JJUSGRQS7RM5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $399,955
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Place of performance
- New York, USA
Award details come from USAspending.gov.
Description
- Abstract
- We are developing a novel CD3-bispecific antibody product, TB-BS1, for the treatment of lung cancer. Lung cancer is the leading cause of cancer deaths in both men and women in the U.S. Each year, with non-small cell lung cancer (nsclc) making up the majority of cases. Nsclc also has one of the lowest survival rates, with 5- year survival for new diagnoses at only 18%. Treatment options remain relatively unchanged over the past decade, despite the emergence of new immunotherapies such as checkpoint inhibitors and car-t cell therapy. The success of these modalities is heterogeneous at best, largely due to the complexity of the tumor microenvironment (TME). Specifically, on-target off-tumor toxicity and reduced immune stimulation within the tumor have limited immunotherapy success. Therefore, exploration of new targets and therapeutic modalities that can specifically and potently direct immune-mediated cancer cell death at the tumor site would provide nsclc patients with a much-needed option. Herein this phase i application, we are advancing TB-BS1 through preclinical proof-of-concept in vivo studies in nsclc. TB-BS1 is built on the FC-inert CD3 duobodyò bispecific antibody platform and has a unique tumor associated antigen (TAA) target, receptor tyrosine kinase orphan receptor 2 (ROR2). ROR2, a WNT signaling membrane receptor that is expressed and active during embryogenesis but is absent from healthy tissues in adults, is a new target that has yet to be validated. We present here a highly specific anti-ROR2 antibody that is built on a clinically validated bispecific platform. We will first determine ROR2 expression in a panel of nsclc tumors as well as in normal human tissue samples. Then we will evaluate the anti-tumor therapeutic effect of TB-BS1 in a proof-of-concept ROR2-positive nsclc humanized mouse model. These results will support the launch of TB-BS1 into full-scale preclinical development for the treatment of ROR2-positive nsclc in a future phase II application.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $399,955 |
Quick answers
Who received award R43CA285040?
R43CA285040 was awarded to Traverse Biotech II Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2023.
How much is award R43CA285040 worth?
$399,955 has been obligated on R43CA285040.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award